Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

EP: 1.Evolving Guidelines: Impact of Gene Therapy and BCG Failure Redefinitions on High-Risk NMIBC Patient Management

EP: 2.Applying Evidence Standards to Guide Gene Therapy Use in BCG-Unresponsive NMIBC

EP: 3.Impact of Real-World Treatment Experience on Gene Therapy Uptake in NMIBC

Now Viewing

EP: 4.Navigating Challenges and Impact on Workflow with New NMIBC Therapies in Practice

EP: 5.Effective Strategies for Clinics Preparing to Implement Gene Therapy Into NMIBC Treatment Workflows

EP: 6.Reducing Clinical Resource Burden: Impact of Less Frequent NMIBC Therapy Administration

EP: 7.How Community-Based Gene Therapy Is Changing Treatment and Improving Quality of Life for Patients With BCG-Unresponsive NMIBC

EP: 8.Understanding NMIBC and Its Risk Factors

EP: 9.Navigating Treatment Burden in NMIBC

EP: 10.When BCG Falls Short: What’s Next for NMIBC Patients?

EP: 11.A New Era: The Rise of Gene Therapy in NMIBC

EP: 12.Where Do We Go From Here? Overcoming Barriers in NMIBC Care

EP: 13.Bridging the Gap Between Clinical Trial Evidence and Real-World Practice in NMIBC

EP: 14.Coverage Criteria and Clinical Evidence Used to Shape Health Plan Formulary Decisions in BCG-Unresponsive NMIBC

EP: 15.Prioritizing Safety and Efficacy: Role of Guidelines in NMIBC Formulary Decisions

EP: 16.Evaluating Cost-Effectiveness of NMIBC Therapies From a Health Plan Perspective

EP: 17.Leveraging Real-World Evidence in NMIBC Therapy Evaluations

Video content above is prompted by the following:

Integration of newer non-muscle invasive bladder cancer (NMIBC) therapies into clinical practice faces several operational barriers that require systematic solutions. Administration logistics present the primary challenge, requiring pharmacy support for receiving, storing and handling these specialized medications. Staff training for proper storage, thawing and administration procedures is essential, along with coordination systems to ensure patients arrive at appropriate times. These logistical requirements can initially overwhelm practices unprepared for the complexity of gene therapy administration.

Provider awareness and institutional restrictions create additional barriers to implementation. Some urologists may lack familiarity with newer therapies, continuing to prescribe outdated treatments like mitomycin for BCG-unresponsive disease. Formulary restrictions, particularly in capitated healthcare settings, may limit access to these newer, more expensive therapies. These systemic barriers require targeted educational initiatives and policy changes to ensure appropriate patient access to evidence-based treatments.

Solutions center on improving data quality and standardizing treatment pathways. Comparative randomized trials are essential for establishing evidence-based treatment selection criteria and reducing unwarranted practice variation. Institutional protocols aligned with guidelines, industry partnerships for training and logistics support, and educational initiatives can help overcome implementation barriers. The development of centralized treatment pathways based on robust comparative data will ultimately reduce practice variation and improve patient outcomes across different healthcare settings.